Madrigal drug meets FDA’s dual targets for NASH, paving way for FDA filing – MedCity News
The lack of therapies for non-alcoholic steatohepatitis, or NASH, has attracted many companies in the search for a cure for this fatty liver disease. Madrigal Pharmaceuticals pushes to the front…